Found: 31
Select item for more details and to access through your institution.
Pharmaceutical good manufacturing practice: Leuplin® production in Japan identifies major international shortcomings.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1167, doi. 10.1007/s10637-021-01080-y
- By:
- Publication type:
- Article
Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1132, doi. 10.1007/s10637-021-01082-w
- By:
- Publication type:
- Article
Correction to: Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1189, doi. 10.1007/s10637-021-01091-9
- By:
- Publication type:
- Article
Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1197, doi. 10.1007/s10637-021-01103-8
- By:
- Publication type:
- Article
Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance).
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1072, doi. 10.1007/s10637-021-01090-w
- By:
- Publication type:
- Article
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1089, doi. 10.1007/s10637-021-01094-6
- By:
- Publication type:
- Article
Dissociated response and clinical benefit in patients treated with nivolumab monotherapy.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1170, doi. 10.1007/s10637-021-01077-7
- By:
- Publication type:
- Article
Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 961, doi. 10.1007/s10637-021-01079-5
- By:
- Publication type:
- Article
Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1106, doi. 10.1007/s10637-021-01076-8
- By:
- Publication type:
- Article
Rapamycin synergizes the cytotoxic effects of MEK inhibitor binimetinib and overcomes acquired resistance to therapy in melanoma cell lines in vitro.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 987, doi. 10.1007/s10637-021-01089-3
- By:
- Publication type:
- Article
A novel methylated analogue of L-Mimosine exerts its therapeutic potency through ROS production and ceramide-induced apoptosis in malignant melanoma.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 971, doi. 10.1007/s10637-021-01087-5
- By:
- Publication type:
- Article
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1081, doi. 10.1007/s10637-021-01086-6
- By:
- Publication type:
- Article
LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1057, doi. 10.1007/s10637-021-01084-8
- By:
- Publication type:
- Article
Discovery of an orally active antitumor agent that induces apoptosis and suppresses EMT through heat shock protein 90 inhibition.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1179, doi. 10.1007/s10637-021-01083-9
- By:
- Publication type:
- Article
First‐in‐human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1047, doi. 10.1007/s10637-021-01081-x
- By:
- Publication type:
- Article
Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1159, doi. 10.1007/s10637-021-01075-9
- By:
- Publication type:
- Article
Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trial.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1113, doi. 10.1007/s10637-021-01074-w
- By:
- Publication type:
- Article
Autophagy promotes oncolysis of an adenovirus expressing apoptin in human bladder cancer models.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 949, doi. 10.1007/s10637-021-01073-x
- By:
- Publication type:
- Article
Screening and identification of potential biomarkers and therapeutic drugs in melanoma via integrated bioinformatics analysis.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 928, doi. 10.1007/s10637-021-01072-y
- By:
- Publication type:
- Article
Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1011, doi. 10.1007/s10637-021-01071-z
- By:
- Publication type:
- Article
System Xc−: a key regulatory target of ferroptosis in cancer.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1123, doi. 10.1007/s10637-021-01070-0
- By:
- Publication type:
- Article
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1099, doi. 10.1007/s10637-020-01056-4
- By:
- Publication type:
- Article
AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1139, doi. 10.1007/s10637-021-01066-w
- By:
- Publication type:
- Article
Identify potential miRNA-mRNA regulatory networks contributing to high-risk neuroblastoma.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 901, doi. 10.1007/s10637-021-01064-y
- By:
- Publication type:
- Article
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1019, doi. 10.1007/s10637-020-01058-2
- By:
- Publication type:
- Article
Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1150, doi. 10.1007/s10637-021-01069-7
- By:
- Publication type:
- Article
A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1036, doi. 10.1007/s10637-020-01055-5
- By:
- Publication type:
- Article
Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1001, doi. 10.1007/s10637-020-01049-3
- By:
- Publication type:
- Article
A novel ligand of the translationally controlled tumor protein (TCTP) identified by virtual drug screening for cancer differentiation therapy.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 914, doi. 10.1007/s10637-020-01042-w
- By:
- Publication type:
- Article
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1028, doi. 10.1007/s10637-020-01054-6
- By:
- Publication type:
- Article